title: [Esthesioneuroblastoma: A single institution's experience and general literature review].
abstract: OBJECTIVE
  Olfactory neuroblastoma or esthesioneuroblastoma is a rare entity among head and neck neoplasms. In this paper, we report the experience of our institution and compare it with a comprehensive review of the literature.
  
  
  METHODS
  We retrospectively analysed clinical and treatment data of patients referred to the Lyon Sud University Hospital (France) for histologically proven olfactive esthesioneuroblastoma.
  
  
  RESULTS
  Ten patients treated between 1993 and 2015 have been analysed. Disease stage at diagnosis, according to the Kadish staging system, was C in 90% of cases. Median follow-up was 136 months. Ten-year overall survival was 90%. Five- and ten-year progression-free survival were 70% and 50%. Nine patients (90%) underwent surgical resection first. Seven of the nine patients who underwent resection (77%) received adjuvant three-dimensional (3D)-conformal radiotherapy (n=7), intensity-modulated radiotherapy (n=1), or volumetric arctherapy (n=1). The mean dose to the tumour volume was 61Gy. None of the patients received elective nodal irradiation. Two patients received concurrent chemotherapy. Five patients (50%) presented with disease recurrence, which was local (n=1), nodal (n=2) and cerebral (n=2).
  
  
  CONCLUSIONS
  Our results are consistent with the literature. Because of the lack of prospective study and the low number of cases in the literature, each institution's experience is of the utmost important to improve standardised management of these tumours.
authors.affiliation: Département de radiothérapie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France. Electronic address: ariane.lapierre@chu-lyon.fr.
authors.forename: A
authors.initials: A
authors.lastname: Lapierre
authors.affiliation: Département de radiothérapie, centre hospitalier universitaire de Marrakech, Marrakech, Maroc.
authors.forename: I
authors.initials: I
authors.lastname: Selmaji
authors.affiliation: Département de radiothérapie, centre hospitalier universitaire de Casablanca, Casablanca, Maroc.
authors.forename: H
authors.initials: H
authors.lastname: Samlali
authors.affiliation: Département de radiothérapie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.
authors.forename: T
authors.initials: T
authors.lastname: Brahmi
authors.affiliation: Département de radiothérapie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.
authors.forename: S
authors.initials: S
authors.lastname: Yossi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018304:Esthesioneuroblastoma, Olfactory / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D005005:Ethmoid Sinus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015182:Lymphatic Irradiation; D008297:Male; D008875:Middle Aged; D009669:Nose Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D020266:Radiotherapy, Conformal; D050397:Radiotherapy, Intensity-Modulated; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome
keywords: Esthesioneuroblastoma; Esthésioneuroblastome; Olfactif; Olfactory; Radiotherapy; Radiothérapie; olfactif/thérapie; olfactory/therapy